BQ123
PreclinicalSmall molecule
BQ123 is one of 47 small molecule programs targeting Vasculitis. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
165 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1NOVOLIN R
Novo NordiskPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Routine Treatment
GSKPreclinical
Sulfonylureas
Eli LillyPreclinical
Henagliflozin
TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BQ123. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- VVanderbilt University